Search results for "NAD"

showing 10 items of 2033 documents

Retention of Vanadium(V), Molybdenum(VI) and Tungsten(VI) by Kaolin

1993

Abstract The ability of kaolin (approximately H2Al2Si2O8 · H2O), a well known clay mineral constituent, to retain V(V) andMo(VI) species from 10−5 and 10−4 M solutions, and W(VI) species from 10−4 M solutions was investigated in the pH range 2–7.5 using a solid/liquid ratio 1:100 (w:v). The equilibration time in the adsorption studies was 72 h, and the shaking time in the desorption studies was 17 h. 0.02 M KCl was used as ionic medium and desorbing liquid. V(V), Mo(VI) and W(VI) were all retained by kaolin to some extent, and the amounts of the elements which could be washed away from kaolin with 0.02 M KCl were very small. The pH dependence of the adsorption was considerable: when added a…

AdsorptionChemistryMolybdenumDesorptionInorganic chemistrySoil Sciencechemistry.chemical_elementKaoliniteIonic bondingVanadiumTungstenClay mineralsAgronomy and Crop ScienceActa Agriculturae Scandinavica, Section B - Soil & Plant Science
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?

2012

Abstract OBJECTIVE: To determine possible prediction of regular menses with aging in anovulatory women with polycystic ovary syndrome (PCOS). DESIGN: Cohort. SETTING: Academic practice. PATIENT(S): A total of 54 anovulatory women with PCOS and 28 age- and weight-matched control subjects. INTERVENTION(S): Blood and ovarian ultrasound at baseline and after 5 years. MAJOR OUTCOME MEASURE(S): Serum antimüllerian hormone (AMH), gonadotropins, androgens, insulin sensitivity, and ovarian ultrasound. RESULT(S): After 5 years, there was a significant decrease in AMH in women with PCOS and control subjects (10 of 54 anovulatory women became ovulatory after 5 years). There was a significant negative c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyAgingSettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectSettore MED/13 - EndocrinologiaBody Mass IndexCohort StudiesPCOS AMH Fertility Ovarian function Ovulation Aging HyperandrogenismPredictive Value of TestsInternal medicinemedicineHumansProspective StudiesProspective cohort studyOvulationmedia_commonUltrasonographyAntimullerian Hormonebusiness.industryOvaryObstetrics and GynecologyMiddle AgedPolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEndocrinologyReproductive MedicinePredictive value of testsCohortAndrogensFemaleInsulin ResistancebusinessBody mass indexBiomarkersGonadotropinsCohort studyAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk fa…

2013

Abstract STUDY QUESTION: What alters cardiovascular and metabolic risk factors with aging in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Lipid parameters, mainly low-density lipoprotein (LDL) cholesterol, increase with aging, but not in women who attain ovulatory cycles. WHAT IS KNOWN ALREADY: Cardiovascular and metabolic parameters tend to increase with aging, but this has not been shown in a prospective longitudinal study in women with PCOS. Correlates of these changes have not been identified. STUDY DESIGN: A prospective cohort of 118 hyperandrogenic women with PCOS who were followed from the age of 20-25 years at 5 year intervals for 20 years. PARTICIPANTS/MATERIALS, SE…

AdultBlood GlucoseOvulationmedicine.medical_specialtyWaistSettore MED/09 - Medicina Internamedia_common.quotation_subjectmedicine.medical_treatmentBiologyBody Mass IndexSettore MED/13 - EndocrinologiaRisk FactorsInternal medicineTotal cholesterolPrevalencemedicineHumansInsulinLongitudinal StudiesGonadal Steroid HormonesOvulationmedia_commonMetabolic SyndromeCompeting interestsInsulinPolycystic ovary syndrome (PCOS)RehabilitationMetabolic riskAge Factorsnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseLipidsSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyReproductive MedicineCardiovascular DiseasesPCOS Cardiovascular risk aging hyperandrogenism ovarian function lipid alterationsFemalelipids (amino acids peptides and proteins)Waist CircumferenceMetabolic syndromePolycystic Ovary Syndrome
researchProduct

Hormone therapy is associated with better body composition and adipokine/glucose profiles

2012

Objective: The aim of this study was to evaluate the possibility of preventing the metabolic health consequences of postmenopausal hypogonadism with the use of long-term hormone therapy (HT). Methods: We used a monozygotic co-twin control design including 10 twin pairs (aged 56-62 y) discordant for HT (duration of HT, 2-10 y). In addition, 14 premenopausal women (aged 29-35 y) who did not use HT were studied to evaluate the differences in metabolic health between the premenopausal and postmenopausal states. Body composition was determined, and waist-to-hip ratio was used as an estimate for fat distribution. Serum sex steroids, sex hormone-binding globulin, and serum lipid and glucose profil…

AdultBlood Glucosenaisetmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentkehon koostumusCo twin controlAdipose tissueAdipokineCarbohydrate metabolismAdipokinesSex Hormone-Binding GlobulinInternal medicineLeukocytesmedicineHumansRNA MessengerGonadal Steroid HormonesMuscle SkeletalChemokine CCL2kehonkoostumusMetabolic healthkaksostutkimusWaist-Hip Ratiobusiness.industryEstrogen Replacement TherapyadipokoinesObstetrics and Gynecologyta3141Twin studyTwins MonozygoticMiddle Agedadipokiinitmedicine.diseaseLipidsPostmenopauseMenopauseEndocrinologyAdipose TissuePremenopauseEstrogenCase-Control StudiesBody CompositionFemaleHormone therapyInsulin ResistancebusinessMenopause
researchProduct

Cross-Country Measurement Invariance and Effects of Sociodemographic Factors on Body Weight and Shape Concern-Related Constructs in Eight Countries.

2020

The aim of this study was to examine the cross-country invariance of five well-established measures of body weight and shape concern-related attitudes and behaviors (i.e., drive for leanness, drive for muscularity, strategies to increase muscle, strategies to lose weight, and weight and shape concerns). A secondary objective was to examine the effects of several sociodemographic factors (age, BMI, socioeconomic status, and gender) on item and latent factor scores of these constructs. A total of 6272 emerging adults (4218 women; Mage = 21.46, SD = 3.11) from Australia, Belgium, Canada, China, Italy, Japan, Spain, and the U.S. completed a self-report online survey as part of a larger study. O…

AdultCross-Cultural ComparisonMale050103 clinical psychologyCanadaChinaSocial PsychologyAdolescentdrive for muscularity050109 social psychologySettore M-PSI/08 - PSICOLOGIA CLINICABody weightBody Mass IndexYoung AdultSex FactorsBelgiumJapanThinnessSurveys and Questionnairesdrive for leannessBody ImageinvarianceHumans0501 psychology and cognitive sciencesMeasurement invarianceSocioeconomic statusGeneral PsychologyApplied PsychologyDriveCross country05 social sciencesBody Weightbody changeAustraliaUnited Statesbody change body image drive for leanness drive for muscularity invariance strategiesAttitudeItalySocioeconomic FactorsSpainstrategiesFemalePsychologyDemographyBody image
researchProduct

Mantenimiento de la lactancia materna exclusiva a los 3 meses posparto: experiencia en un departamento de salud de la Comunidad Valenciana

2019

Resumen: Objetivos: Determinar la prevalencia de la lactancia materna exclusiva (LME) a los 3 meses posparto, y conocer las causas que contribuyen al abandono precoz. Diseño: Estudio observacional y restrospectivo. Emplazamiento: Departamento de Salud de la Ribera, Valencia, España. Participantes: Niños nacidos entre diciembre de 2012 y enero de 2017. Mediciones principales: prevalencia de lactancia materna al alta y de LME a los 3 meses. Motivos de abandono de LME. Determinación de Chi-cuadrado entre variables categóricas. Metodología: Las mujeres fueron entrevistadas en el posparto y a los 3 meses posparto, teniendo en cuenta las variables asociadas al inicio de la lactancia y su continua…

AdultHealth Knowledge Attitudes PracticeBreastfeeding03 medical and health sciences0302 clinical medicineInfants nadonsEarly weaningHumans030212 general & internal medicineProspective Studieslcsh:R5-920030504 nursingLactancia maternaPostpartum PeriodGeneral MedicineDestete precozOriginalesBreast FeedingRisk factorsSpainFemale0305 other medical scienceFamily Practicelcsh:Medicine (General)Factores de riesgoFollow-Up StudiesAtencion Primaria
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency)

1984

We describe 5 adult women with severe hirsutism due to late onset 21-hydroxylase deficiency. Diagnosis was performed on the finding of high serum 17-hydroxyprogesterone (17OHP) levels with a marked hyperresponse to an ACTH test. The endocrine study showed in most patients a gonadotropin behavior similar to that observed in classical polycystic ovary (PCO) syndrome. Prolactin levels were slightly increased in basal conditions and presented an exaggerated response to TRH stimulation.

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismLate onsetEndocrinologyAdrenocorticotropic HormoneInternal medicineHydroxyprogesteronesmedicineHumansEndocrine systemGonadal Steroid HormoneshirsutismAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneVirilization21-HydroxylaseLuteinizing Hormonemedicine.diseasePolycystic ovaryProlactinProlactinEndocrinologySteroid Hydroxylasesbiology.proteinFemaleSteroid 21-HydroxylaseFollicle Stimulating Hormonemedicine.symptomGonadotropinbusinesshormones hormone substitutes and hormone antagonistsJournal of Endocrinological Investigation
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct